FDA Structured Product Label
Anipryl®
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
- Sponsor
- Zoetis Inc.
- NADA
- 141-080
- Status
- OTC
- Form
- Tablet
- Route
- Oral
- Species
- Dog, No Use Class Stated Or Implied
Composition / specifications
Each tablet contains either 2, 5, 10, 15, or 30 milligrams of selegiline hydrochloride.
Dogs
Indication
For the control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH).
Dosage
1.0 mg/kg once daily,
preferably administered in the morning. If no improvement
is observed after 2 months of therapy, dosage may be
increased to a maximum of 2.0 mg/kg once daily. If no
improvement is seen after 1 month at the higher dose or
if at any time clinical signs progress, the dog should be
re-evaluated.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Anipryl should not be administered at doses exceeding those recommended (0.5-2.0 mg/kg once daily).
Concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended.
Indication
For the control of clinical signs associated with canine cognitive dysfunction syndrome (CDS)
Dosage
0.5–1.0 mg/kg once daily, preferably administered in the
morning. Initially, dogs should be dosed to the nearest
whole tablet. Adjustments should then be made based on
response and tolerance to the drug.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Anipryl should not be administered at doses exceeding those recommended (0.5-2.0 mg/kg once daily).
Concurrent use of Anipryl with ephedrine or potential MAO inhibitors, such as amitraz, is not recommended.